About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

Robot Based Gait Training Therapy for Pediatric Population With Cerebral Palsy Using the CPWalker

Clinicaltrials.gov identifier NCT03937700

Recruitment Status Recruiting

First Posted May 6, 2019

Last update posted August 20, 2020

Study Description

Brief summary:

This trial is being conducted to determine if the CPWalker can be used as a gait training intervention for pediatric patients with gait impairments due to cerebral palsy

  • Condition or Disease:Cerebral Palsy
  • Intervention/Treatment: Device: CPWalker Robotic Exoskeleton
  • Phase: N/A
Detailed Description

Objectives: 1. To determine the use of the CPWalker rehabilitation platform, a robotic device composed by an exoskeleton linked to a walker that provides support and balance, as a gait training intervention in the pediatric cerebral palsy population. 2. To create and define detailed guidelines consisting of robotic based treatment methods for gait rehabilitation. Hypothesis: 1. CPWalker can be used as a gait training intervention for pediatric patients with gait impairments due to cerebral palsy 2. Performing lower limb training in conjunction with active head and trunk control therapies will improve functional gait levels 3. Following 16-24 CPWalker training sessions, persons with cerebral palsy will show improvements in functional mobility when comparing pre-training measurements to post-training measurements Procedures: Participants will engage in an 8-week training program, consisting of 2-3 sessions per week based on the level of gait impairment. Percentage range of motion (ROM), partial body weight support (PWBS), and gait velocity are the principal parameters under variation during training. Additionally, screening, baseline and post-training testing sessions will be conducted

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 30 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Robot Based Gait Training Therapy for Pediatric Population With Cerebral Palsy Using the CPWalker
  • Actual Study Start Date: July 2019
  • Estimated Primary Completion Date: June 2024
  • Estimated Study Completion Date: June 2024
Arms and interventions
Arm Intervention/treatment
Experimental: CPWalker Robotic-Assisted Gait Training
Each subject will participate in 16-24 gait training sessions in the CPWalker over the course of 8 weeks with each session lasting up to 2 hours
Device: CPWalker Robotic Exoskeleton
The CPWalker rehabilitation platform is a robotic device composed by an exoskeleton linked to a walker that provides support and balance to a child during overground training. The device is able to implement user's partial body weight support (PBWS) and allows the adaptation of exercises to the patient's capabilities by means of individual controllers for each joint, which increases the modularity of the system. Each joint of the CPWalker can operate in a range of modes with varied levels of robotic assistance or resistance
Outcome Measures
  • Primary Outcome Measures: 1. 10-Meter Walk Test [ Time Frame: Change from baseline gait speed at 8 weeks ]
    This test will examine the patient's gait speed. Patients will be directed to walk at their preferred and maximum but safe speed. Patients will be positioned 1 meter before the start line and instructed to walk the entire 10-meter distance and past the end line approximately 1 meter. The distance before and after the course are meant to minimize the effect of acceleration and deceleration. Time will be recorded using a stopwatch and recorded to the one hundredth of a second.
  • Secondary Outcome Measures: 1. 6-Minute Walk Test [ Time Frame: Change from baseline distance ambulated at 8 weeks ]
    This test measures the distance a subject can walk indoors on a flat, hard surface in a period of 6 minutes, using assistive devices, as necessary. The test is a reliable and valid evaluation of functional exercise capacity and is used as a sub-maximal test of aerobic capacity and endurance. The test is patient self-paced and assesses the level of functional capacity. Patients are allowed to stop and rest during the test, however, the timer does not stop. If the patient is unable to complete the time, the time stopped is noted and reason for stopping prematurely is recorded. This test will be administered while wearing a mask to measure oxygen consumption.
  • 2. GAITRite Data Collection [ Time Frame: Change from baseline gait quality at 8 weeks ]
    The GAITRite system automates measuring temporal and spatial gait parameters via an electronic walkway connected to a computer. The GAITRite electronic walkway contains sensor pads encapsulated in a carpet to collect gait information. The system can be laid over any flat surface. The GAITRite electronic walkway for the study shall be a minimum of 14 feet long. The GAITRite data capture was chosen as measurement of the patient's overall gait quality. Patients will be asked to walk at a self-selected speed across the GAITRite electronic walkway with at least a two meter "flying start" to compensate for initial acceleration.
  • 3. Pediatric Balance Scale [ Time Frame: Change from baseline balance score at 8 weeks ]
    This test is a 14-item objective measure designed to assess static balance in pediatric populations. The functional activities that are assessed include sitting and standing balance during transfers, altered base of support, reaching, turning, eyes open and closed. Each item is scored from 0 to 4 points. The maximum score is 56 points.
  • 4. Selective Control Assessment of Lower Extremity (SCALE) [ Time Frame: Change from baseline selective voluntary motor control at 8 weeks ]
    This clinical tool quantifies selective voluntary motor control of the lower extremities in patients with cerebral palsy.
  • 5. Gross Motor Function Measure (GMFM-88) dimensions D (standing) and E (walking) [ Time Frame: Change from baseline gross motor function at 8 weeks ]
    This test measures the change in gross motor function with intervention in children with cerebral palsy
  • 6. Child and Adolescent Scale of Participation [ Time Frame: Change in children's baseline participation in activities at 8 weeks ]
    This questionnaire measures the extent to which children participate in home, school, and community activities as reported by family caregivers.
  • 7. Gillette Functional Assessment Questionnaire (FAQ) [ Time Frame: Change in baseline report of ambulatory function at 8 weeks ]
    This is a proxy-report measure that includes a ten-level classification of ambulatory function and 22 functional locomotor activities
Eligibility Criteria
  • Ages Eligible for Study: 11 to 21 Years (Child, Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Diagnosis of Cerebral Palsy with spastic diplegia

- Gross Motor Function Classification System score of 2-4

- Age 11-21 at time of enrollment

- Maximum weight of 75kg

- Height range of approximately 110cm to 170cm

- Ability to understand and follow verbal cues

- Lower limb measurements meet specifications of CPWalker

- Cognition sufficient to communicate pain or discomfort and follow one step direction
from the investigator

Exclusion Criteria:

- Any orthopedic surgeries less than 3 months prior to study enrollment or ongoing botox
injections

- Severe musculoskeletal deformities affecting safe and comfortable fit into the
exoskeleton as determined by the investigator. Patients may be able to wear their AFOs
in the CPWalker if it allows for safe fit.

- Unhealed wounds/lesions

- Critical motor control alterations such as dystonia, choreoathetosis, or ataxia

- Aggressive or self-harming behavior

- Severe cognitive impairments that prevent a subject from being able to understand the
exercises an/or interact with the study staff

Contacts and Locations
Contacts

Contact: Sara Prokup, DPT 312-238-1355 sprokup@ricres.org

Contact: Matt McGuire, DPT 312-238-3457 mmcguire@ricres.org

Locations

United States, Illinois
Shirley Ryan AbilityLab
Chicago

Sponsors and Collaborators

Shirley Ryan AbilityLab

Investigators

Principal Investigator: Arun Jayaraman, PT, PhD Shirley Ryan AbilityLab

More Information
  • Responsible Party: Shirley Ryan AbilityLab
  • ClinicalTrials.gov Identifier: NCT03937700 History of Changes
  • Other Study ID Numbers: STU00206310
  • First Posted: May 6, 2019 Key Record Dates
  • Last Update Posted: August 20, 2020
  • Last Verified: August 2020
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Cerebral Palsy